SAM
ACAD icon

Smartleaf Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Smartleaf Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.6K Hold
1,375
– – ﹤0.01% 1702
2026
Q1 		$29K Sell
1,375
-1,221
-47% -$29.2K ﹤0.01% 1766
2025
Q4 		$69.3K Buy
2,596
+884
+52% +$21.1K ﹤0.01% 1392
2025
Q3 		$36.5K Buy
1,712
+885
+107% +$20.9K ﹤0.01% 1549
2025
Q2 		$18.3K Buy
827
+279
+51% +$5.19K ﹤0.01% 1593
2025
Q1 		$9.35K Sell
548
-311
-36% -$5.65K ﹤0.01% 1950
2024
Q4 		$14.3K Buy
859
+575
+202% +$9.28K ﹤0.01% 1832
2024
Q3 		$4.46K Sell
284
-141
-33% -$2.35K ﹤0.01% 2176
2024
Q2 		$6.96K Buy
+425
New +$6.86K ﹤0.01% 1619

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Smartleaf Asset Management's ACAD Position: Q2 2026 in Review

Smartleaf Asset Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 1,375 shares worth $34.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1702.

Smartleaf Asset Management first reported a position in ACAD in Q2 2024 and has held it in 9 quarters since. The position peaked at $69.3K in Q4 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Smartleaf Asset Management held 1,375 shares of Acadia Pharmaceuticals worth $34.6K as of Q2 2026.
  • Smartleaf Asset Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1702 holding.
  • Smartleaf Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Smartleaf Asset Management's Acadia Pharmaceuticals position peaked at $69.3K in Q4 2025.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.